A strong antioxidant, alpha-lipoic acid (ALA) has garnered a lot of attention due to its efficacy as a therapy for diabetic neuropathy, a common and debilitating side effect of diabetes that manifests as nerve damage and chronic pain. The clinical data in favour of ALA’s usage is compiled here, along with an exploration of the processes by which it affects diabetic neuropathy. Because ALA is soluble in lipids and water, it may function as a flexible antioxidant in various cellular contexts. This property makes ALA unique. Oxidative stress, a major factor responsible for the aetiology of diabetic neuropathy, can be reduced by removing free radicals, reviving other antioxidants, and increasing mitochondrial function. Additionally, ALA improves glucose absorption, which may aid in glycaemic control and further reduce the risk of nerve damage. Clinical trials have shown that, when taken in sufficient dosages, ALA dramatically lowers neuropathic pain, enhances sensory function, and may even partially reverse nerve damage. Patients with early-stage neuropathy benefit most from it. To ascertain the optimal dosage, course of medication, and long-term safety, further study is needed. By targeting the metabolic and biochemical components of diabetic neuropathy, the combination of ALA with lifestyle changes, including a healthier diet and more exercise, may provide an even larger therapeutic benefit.